c Ceftazidime-avibactam is active against most Enterobacteriaceae isolates with KPC carbapenemases. We investigated whether this activity could be compromised by mutation. Single-step and multistep selections were attempted using ceftazidime-avibactam (avibactam fixed at 1 or 4 g/ml) versus two strains each of Enterobacter cloacae and Klebsiella pneumoniae, all with the KPC-3 enzyme. Mutant bla KPC alleles were sequenced, and their parentage was confirmed by typing. Ceftazidime-avibactam selected mutants at up to 16؋ MIC, with frequencies of ca. 10
A
vibactam is the first diazabicyclooctane ␤-lactamase inhibitor to reach advanced clinical development. It inhibits class A ␤-lactamases, including KPC types and AmpC types (1, 2) . Activity against class D ␤-lactamases varies with the particular enzymes. Metallo (class B)-␤-lactamases are unaffected. The combination of ceftazidime with avibactam was approved in February 2015 by the U.S. Food and Drug Administration for use in complicated intra-abdominal and urinary tract infections. Combinations with ceftaroline fosamil and aztreonam are in the earlier stages of development (ceftaroline fosamil is a prodrug of ceftaroline, to which it is rapidly converted following intravenous [i.v.] administration).
The ability of avibactam to inhibit KPC ␤-lactamases is of particular interest, given that these carbapenemases are expanding globally, with dramatic proliferation in, e.g., Italy, Greece, Brazil, the United States, and Israel (3) . Enterobacteriaceae that produce KPC carbapenemases typically are resistant to all ␤-lactam antibiotics except temocillin, which retains strainvariable activity (4); most are also resistant to multiple other agents besides ␤-lactams (3). Although KPC enzymes are class A ␤-lactamases, strains that produce these enzymes are resistant to the available penicillin-clavulanate and penicillin-penicillanic acid sulfone combinations, apparently because the carbapenemases can inactivate these ␤-lactamase inhibitors (5) .
It is important, however, to assess the vulnerabilities of new ␤-lactamase inhibitor combinations such as ceftazidimeavibactam to spontaneous mutational resistance. Amino acid substitutions in the TEM and SHV enzymes can reduce binding of clavulanate and penicillanic acid sulfones (6) , although inhibitor-resistant TEM mutants appear not to have proliferated to the same extent as cephalosporin-hydrolyzing extendedspectrum ␤-lactamase (ESBL) mutants and are rarely selected in vivo (7) . Much less is known as yet about the potential of diazabicyclooctane combinations to select resistance. Our previous work (8) with ceftaroline-avibactam found selection in vitro of (i) a CTX-M-15 ␤-lactamase mutant with a Lys237Gln substitution, (ii) mutants of AmpC-derepressed Enterobacter strains with large deletions (amino acids 213 to 226) in the AmpC ⍀ loop, and (iii) mutants of AmpC-derepressed Enterobacter strains with loss of OmpC/F porins, sometimes combined with substitutions to Asn346 in the C terminus of AmpC, a residue recently shown to be involved in the binding of avibactam (9) . On the other hand, we failed to select stable resistance to ceftarolineavibactam in Enterobacteriaceae with KPC carbapenemases, or in those with other ESBLs besides CTX-M-15; moreover, the ceftaroline-avibactam-selected CTX-M-15 mutant lost its ability to confer resistance to other cephalosporins besides ceftaroline. Breakthrough of variants with reduced susceptibility was not observed with ceftazidime-avibactam in neutropenic and immunocompetent mouse thigh and lung infection models performed with cef-changes. Briefly, the PEG solution (20% [wt/vol] PEG-2.5 M sodium chloride) was added to the DNA, and the sample was mixed and incubated at room temperature for 30 min, followed by centrifugation for 45 min at 13,000 rpm and 4°C. The pellet was washed twice with ethanol and resuspended in molecular-grade water. Amplicons were sequenced using the primers 6560U and 8848L (above) as well as a primer designed in this work: 6560U_1A (5=-CGGACGCGAGGAAGCGAACC-3= 
RESULTS
␤-Lactamase gene profiles. DNA arrays confirmed the presence of bla KPC in all four parent strains, and sequencing indicated the KPC-3 variant in all cases. K. pneumoniae H105180643 additionally had an SHV ESBL with a Gly238Ser substitution, and both E. cloacae strains had genes encoding CTX-M-group 9 ESBLs. Although K. pneumoniae NCTC 13438 was an ST258 variant, it lacked evidence of the SHV ESBLs commonly found in this lineage, although classical bla SHV was detected. All four strains had bla TEM-1 , with no ESBL mutations detected.
Mutant selection frequencies. Mutants with increased ceftazidime-avibactam MICs were selected from all four strains, using avibactam at either 1 or 4 g/ml (Table 1) . At 2ϫ MIC, frequencies were from 10 Ϫ6 to 10 Ϫ9 . These frequencies diminished at higher MIC multiples, but remained around 10 Ϫ9 for three of the four strains at 16ϫ MIC for at least one of the avibactam concentrations. It may appear counterintuitive that mutant frequencies were sometimes higher with 4 g/ml than 1 g/ml avibactam, but it should be recognized that starting MICs of ceftazidime with 4 g/ml avibactam were lower than those with 1 g/ml, reducing the barrier to selection. Mutants with raised MICs were also selected in broth in a multistep procedure. To confirm that the mutants were derived from their parents and were not contaminants, we confirmed the consistency of the VNTR (K. pneumoniae) and PFGE profiles (E. cloacae) for representatives within each series, selected as showing diverse changes in carbapenem MICs (below) in parallel with raised ceftazidime-avibactam MICs. In all cases, the mutants' profiles were indistinguishable from those of their parents, confirming parentage.
Phenotypes of mutants. MIC distributions for 101 mutants (7 to 33 per parent strain) selected in single-step (SS) and multistep procedures are shown in Table 2 . There was little or no relationship between the selective MIC multiple and the shifts in ceftazidime-avibactam MICs observed, justifying pooling of data for mutants selected under different conditions.
The MICs of ceftazidime with avibactam at 1 g/ml rose from 1 to 8 g/ml for the parent strains to 16 to Ͼ256 g/ml for their mutants; those of ceftazidime with avibactam at 4 g/ml rose from 0.25 to 1 g/ml to 4 to 128 g/ml (generally 8 to 64 g/ml). The MICs of ceftaroline-avibactam were much less affected, being raised from 0.5 to 1 g/ml to 1 to 8 g/ml. The MICs of the other ␤-lactams, particularly carbapenems, were often reduced. Thus, among the 31 ceftazidime-avibactam-selected mutants derived from K. pneumoniae NCTC 13438 (with a VNTR type corresponding to ST258), five showed reductions in meropenem MICs, from Ͼ32 g/ml to 2 g/ml, and, among 30 mutants derived from K. pneumoniae H105180643, only one retained the parental level of resistance to ertapenem and meropenem (MICs of Ͼ16 to 32 g/ml), whereas 21 became susceptible to meropenem at Յ1 g/ml and 13 to ertapenem at 0.5 g/ml. In the case of E. cloacae H112260226, 10/33 mutants showed no change in the meropenem MIC (Ϯ1 doubling dilution) from the parental value of 8 g/ml, whereas 22 became susceptible at Յ1 g/ml. For ertapenem, 11/33 continued to exhibit parental MICs of around 16 g/ml, whereas the MICs for the remainder fell to 1 to 4 g/ml and in one case to 0.25 g/ml. Last, 6/7 mutants of E. cloacae H120900216 showed dramatic MIC reductions for meropenem and ertapenem, from Ն16 g/ml to Յ0.5 g/ml, whereas the MICs for the remaining mutant remained at 4 g/ml (meropenem) and 8 g/ml (ertapenem). MIC shifts were consistent throughout between the two carbapenems, i.e., a mutant that showed a marked MIC reduction to meropenem showed a reduction also for ertapenem.
Many of the mutants also showed reductions in the MICs of piperacillin-tazobactam and those of cephalosporins other than ceftazidime and ceftaroline. Unlike for carbapenems, however, the analysis here is complicated by the fact that, except for K. pneumoniae NCTC 13438, the test strains had secondary SHV or CTX-M ESBLs, which would continue to contribute to cephalosporin resistance in their mutants irrespective of whether the KPC enzyme lost activity. The ciprofloxacin and gentamicin MICs remained consistent within each mutant series.
Molecular profiling of mutants. We sequenced bla KPC from 13 mutants (Table 3) and their corresponding parents. These mutants were selected as showing a diversity of shifts in the MICs of comparator antibiotics and represented all four parents. VNTR and PFGE profiles were consistent between parents and mutants within each series. All four parents were reconfirmed to have classical bla . The nucleotide sequence analysis of bla KPC from the mutants revealed point mutations or insertion changes in all but one case. In 10 of the mutants, the alteration occurred within or immediately C-terminal to the ⍀ loop, which extends from Arg164 (standard numbering for class A ␤-lactamases [19] , corresponding to Arg163 in the actual sequence) to Asp179. The most frequent change seen, observed in four mutants from three parents, was Asp179Tyr, whereas other changes in the loop or immediately adjacent to it included (i) Asp163Gly, (ii) Pro174Leu, (iii) insertion of serine between amino acids 180 and 181, (iv) insertion of two serine residues between amino acids 181 and 182, and (v) insertion of Arg-Ala-Thr-Thr-Ser-Ser-Pro between positions 183 and 184. Two mutants lacked modifications around the ⍀ loop but had more remote changes, namely, Thr243Pro and insertion of Ala-Arg between positions 265 and 266. Only mutant 4 (SS) of K. pneumoniae NCTC 13438 lacked detected changes to the sequence of bla KPC . Uniquely among the mutants studied in detail, this variant showed near-identical (8-to 16-fold) MIC rises for both ceftazidime-avibactam and ceftaroline-avibactam. Moreover, and unlike most other mutants, it showed no reductions in resistance to other ␤-lactams. It is plausible that its behavior reflected a generalized reduction in permeability.
DISCUSSION
Based on previous experience with ceftaroline-avibactam (8), we initiated these studies with little expectation of selecting mutants other, perhaps, than those with permeability lesions. The results confounded these expectations. While mutant frequencies remained in the 10 Ϫ9 range at MIC multiples of 4-to 16-fold, it was easier to select mutants of KPC-3-producing Enterobacteriaceae that were resistant to ceftazidime-avibactam than it had been to select mutants that were resistant to ceftaroline-avibactam, where mutation frequencies for strains with KPC carbapenemases were consistently below the detection limit of 10 Ϫ9 despite ceftaroline being more vulnerable to ␤-lactamases than ceftazidime in general (20) .
Most of the mutants selected here showed smaller MIC rises to ceftaroline-avibactam than to ceftazidime-avibactam, consistent with the observation that direct selection with ceftaroline-avibactam was more difficult. Also striking is that fact that the MICs of other ␤-lactams, particularly those of meropenem and ertapenem, were reduced for many of the mutants. A lack of generalized resistance to avibactam combinations suggests a ceftazidime-related effect, rather than evolution of avibactam resistance per se by the KPC enzymes. Plausible mechanisms would be an increase in enzymatic affinity for ceftazidime, resulting in a reduced K m , or a change in the balance of ceftazidime acylation versus deacylation. Either of these mechanisms would effectively lead to ceftazidime protecting the enzyme from avibactam. Amino acid substitutions that change ␤-lactamase interactions with ceftazidime are well known: both TEM and CTX-M ESBLs can undergo mutations that specifically increase "ceftazidimase" activity, as with CTX-M-15 ␤-lactamase versus CTX-M-3 (21, 22) . Moreover, mutations that increase acylation relative to deacylation for ceftazidime have been described for KPC carbapenemases (23) as well as for TEM ESBLs (24) . Crucially, Levitt et al. (23) described several substitutions to Arg164 in the ⍀ loop of KPC ␤-lactamase, generated by site-directed mutagenesis, that increased resistance to ceftazidime by changing the balance between acylation and deacylation. Exactly as with many of our "natural," mutants, these showed reduced resistance to imipenem, cefotaxime, and cefepime. Levitt et al. (23) did not test avibactam combinations against their mutants. While none of our mutants had changes to Arg164, the majority had substitutions within the ⍀ loop or insertions immediately C-terminal to it. The most common single mutation seen was Asp179Tyr, replacing the residue that ordinarily forms a salt bridge with Arg164 to stabilize the ⍀ loop. It is clearly plausible that changes to this site therefore might exert effects similar to those at Arg164, and this view is supported by the results of Winkler et al. (25) , who found that multiple substitutions to Asp179 degraded the ability of the KPC-2 enzyme to confer resistance to ampicillin, aztreonam, and imipenem while generally retaining the ability to confer ceftazidime resistance. Once again, the activities of avibactam combinations were not reported.
Other factors may have contributed to the resistance of some of (SS), which showed broad increases in resistance without the reductions in resistance to some comparator agents. We have not excluded possible changes to the SHV ESBL of K. pneumoniae H105180643 or to the CTX-M-group 9 enzymes of the two Enterobacter species. Even unchanged, these enzymes no doubt contributed to resistance to unprotected cephalosporins. Nevertheless, it is implausible that changes to the coproduced ESBLs were the primary determinant of the present findings since (i) there was a clear association between the mutations of bla KPC and the ceftazidime-avibactam resistance, (ii) the mutations selected here had similar effects, in reducing resistance to multiple comparator ␤-lactams, to analogous site-directed mutations introduced to bla KPC in the laboratory, (iii) putative changes to the coproduced ESBLs evidently cannot explain the reductions in carbapenem resistance, and (iv) similar results were obtained with K. pneumoniae NCTC 13438, which lacked secondary ESBLs, and the other strains, which had these enzymes.
Our data show the potential for the emergence of ceftazidimeavibactam resistance via mutations in bla KPC . Most often these remodeled the enzyme's ⍀ loop. Only time and experience will reveal whether such mutants are selected at infection sites or in the gut flora or are a laboratory curiosity. Selection of resistance has not been reported in animal infection models nor in phase II clinical trials with ceftazidime-avibactam (26, 27) , although these only examined the infection sites and not the gut flora. Moreover, although single point mutations to bla TEM and bla SHV can lead to production of enzyme variants resistant to clavulanate and penicillanic acid sulfones, this seems to be a rare event in the clinic (28) . Furthermore, it is plausible (but unproven) that the reductions in resistance engendered in other ␤-lactams may counterselect these mutations at a hospital level in milieux where a diversity of antibiotics are used. What is more, the selection experiments were done using fixed avibactam concentrations, whereas, at the infection site or in the gut, bacteria with KPC carbapenemases are exposed to changing avibactam concentrations and to changing ceftazidime/avibactam concentrations ratios, and these differences may modulate selectivity.
The observations should, however, be a consideration, along with spectrum and pharmacokinetic compatibility, in the development of ␤-lactamase inhibitor combinations, indicating that the choice of partner agent can affect the potential for mutational resistance.
